BioNTech’s Multi-Modality Play Outpaces Moderna’s mRNA-Focused Pipeline

By /

After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.

Scroll to Top